Browsing by Author "Čolovic, Nataša (6701607753)"

Skin involvement in Hodgkin's disease (HD) is most often a secondary phenomenon representing a rare, late manifestation of dissemination of the disease heralding a grave prognosis. Primary cutaneous HD is very unusual, being reported in 0.5-3.4% of all patients. Based on the introduction of immunohistochemistry for better detection and classification, we report a case with an ostensibly isolated primary cutaneous HD who developed multiple cutaneous lesions 5 years before enlargement of the lymph node involved during relapse. Pathohistology of skin lesions and the involved lymph node indeed showed the same subtype (mixed cellularity) of HD characterized by the presence of CD15+, CD30+, CD45RO- cell-surface markers and by the presence of Epstein-Barr virus+ marker-analyzed immunohistochemistry.

Introduction. Myelodysplastic/myeloproliferative neoplasms represent a group of rare hematologic malignancies with con-comitant characteristics of two different disorders. There are cytopenias and cytoses with dysplastic morphology in the circu-lating blood and hyperplastic bone marrow, respectively. Many cytogenetic and molecular features have been found in this rare entity, but t(2;11)(p21;q23)del(5) (q22;q33) has not been de-scribed so far. Case report. We present a patient with myelo-dysplastic syndrome, subtype refractory anemia without ringed sideroblasts, with unique translocation t(2;11)(p21;q23) associ-ated with del(5)(q22;q33) in the karyotype. Fluorescence in situ hybridization analysis did not detect mixed-lineage leukemia (MLL) rearrangement, which can be found in other hematolog-ic malignancies with this translocation. After a year on support-ive treatment with packed red cells, thrombocytosis developed with a concurrent increase in white blood cells and the Janus kinase-2 gene mutation. This confirmed the presence of myel-odysplastic/myeloproliferative neoplasms. Due to the high platelet count, the cerebrovascular insult has occurred. The pa-tient was treated supportively and with lenalidomide. After in-troducing the lenalidomide steadily, the patient's condition im-proved, the peripheral blood count normalized, and he became transfusion independent. Conclusion. Patients with the cyto-genetic finding of t(2;11)(p21;q23) associated with del(5)(q22;q33) but without MLL rearrangement and with Ja-nus kinase-2 gene mutation presence, respond to lenalidomide therapy and have relatively longer overall survival. © 2021 Inst. Sci. inf., Univ. Defence in Belgrade. All rights reserved.